Time filter

Source Type

Wang X.,Peking Union Medical College | Niu H.,Peking Union Medical College | Fan Q.,Zhengzhou University | Lu P.,The First Affiliated Hospital of Xinxiang Medical College | And 9 more authors.
Oncotarget | Year: 2016

This study aimed to search for a molecular marker for targeted epithelial growth factor receptor (EGFR) inhibitor Icotinib by analyzing protein expression and amplification of EGFR proto-oncogene in esophageal squamous cell carcinoma (ESCC) patients. Immunohistochemistry and fluorescence in situ hybridization (FISH) was used to assess EGFR expression and gene amplification status in 193 patients with ESCC. We also examined the association between EGFR overexpression and the efficacy of a novel EGFR TKI, icotinib, in 62 ESCC patients. Of the 193 patients, 95 (49.2%) patients showed EGFR overexpression (3+), and 47(24.4%) patients harbored EGFR FISH positivity. EGFR overexpression was significantly correlated with clinical stage and lymph node metastasis (p<0.05). In addition, EGFR overexpression was significantly correlated with EGFR FISH positivity (p<0.001). Among the 62 patients who received icotinib, the response rate was 17.6% for patients with high EGFR-expressing tumors, which was markedly higher than the rate (0%) for patients with low to moderate EGFR-expressing tumors (p=0.341). Furthermore, all cases responded to icotinib showed EGFR overexpression. In conclusion, our study suggests that EGFR overexpression might potentially be used in predicting the efficacy in patients treated with Icotinib. These data have implications for both clinical trial design and therapeutic strategies.


Wu C.,Peking Union Medical College | Wang Z.,U.S. National Institutes of Health | Wang Z.,SAIC | Song X.,Xinxiang Medical University | And 165 more authors.
Nature Genetics | Year: 2014

We conducted a joint (pooled) analysis of three genome-wide association studies (GWAS) of esophageal squamous cell carcinoma (ESCC) in individuals of Chinese ancestry (5,337 ESCC cases and 5,787 controls) with 9,654 ESCC cases and 10,058 controls for follow-up. In a logistic regression model adjusted for age, sex, study and two eigenvectors, two new loci achieved genome-wide significance, marked by rs7447927 at 5q31.2 (per-allele odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.82-0.88; P = 7.72 × 10-20) and rs1642764 at 17p13.1 (per-allele OR = 0.88, 95% CI = 0.85-0.91; P = 3.10 × 10-13). rs7447927 is a synonymous SNP in TMEM173, and rs1642764 is an intronic SNP in ATP1B2, near TP53. Furthermore, a locus in the HLA class II region at 6p21.32 (rs35597309) achieved genome-wide significance in the two populations at highest risk for ESSC (OR = 1.33, 95% CI = 1.22-1.46; P = 1.99 × 10-10). Our joint analysis identifies new ESCC susceptibility loci overall as well as a new locus unique to the population in the Taihang Mountain region at high risk of ESCC. © 2014 Nature America, Inc. All rights reserved.


PubMed | Xinjiang Medical University, The First Peoples Hospital of Shangqiu, Shantou University, Zhengzhou University and 43 more.
Type: Journal Article | Journal: Nature genetics | Year: 2014

We conducted a joint (pooled) analysis of three genome-wide association studies (GWAS) of esophageal squamous cell carcinoma (ESCC) in individuals of Chinese ancestry (5,337 ESCC cases and 5,787 controls) with 9,654 ESCC cases and 10,058 controls for follow-up. In a logistic regression model adjusted for age, sex, study and two eigenvectors, two new loci achieved genome-wide significance, marked by rs7447927 at 5q31.2 (per-allele odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.82-0.88; P = 7.72 10(-20)) and rs1642764 at 17p13.1 (per-allele OR = 0.88, 95% CI = 0.85-0.91; P = 3.10 10(-13)). rs7447927 is a synonymous SNP in TMEM173, and rs1642764 is an intronic SNP in ATP1B2, near TP53. Furthermore, a locus in the HLA class II region at 6p21.32 (rs35597309) achieved genome-wide significance in the two populations at highest risk for ESSC (OR = 1.33, 95% CI = 1.22-1.46; P = 1.99 10(-10)). Our joint analysis identifies new ESCC susceptibility loci overall as well as a new locus unique to the population in the Taihang Mountain region at high risk of ESCC.


Guo H.,Huazhong University of Science and Technology | Jin Y.,Institute for Environmental Health and Related Product Safety | Cheng Y.,Institute for Environmental Health and Related Product Safety | Lin S.,Institute for Environmental Health and Related Product Safety | And 8 more authors.
Chemosphere | Year: 2014

In utero exposure to organochlorine pesticides (OCPs) is thought to be potentially harmful to fetal devel- opment. We aimed to investigate the associations of maternal and cord serum OCPs levels with infant birth weight in China. In this study, we measured serum levels of 18 OCPs in 81 mother-infant pairs, including DDT, hexachlorocyclohexanes (BHC), hexachlorobenzene (HCB), heptachlors, chlordanes, endo- sulfan-I, and mirex using a high-resolution-gas-chromatography with high-resolution-mass-spectrome- try method. We found that p,p'-DDE and β-BHC had the highest detection rate in both maternal and cord blood serum (97.2% and 96.7%, respectively), followed by HCB (93.0%, 51.7%), p,p'-DDT (88.7%, 36.7%), and p,p'-DDD (83.1%, 60.0%). Among all OCPs, the concentration of p,p'-DDE was the highest (mothers geo- metric mean (GM): 203.54 ng g-1, newborns GM: 116.14 ng g-1), followed by HCB (70.62 ng g-1, 65.16 ng g-1), and β-BHC (67.67 ng g-1, 33.39 ng g-1). Multiple linear regression analyses showed that each 1 ng g-1 increment of cord serum p,p'-DDE, total DDT, and β-BHC was associated with a 0.10 g, 0.10 g, and 0.92 g decrease in infant birth weight, respectively, and as the cord serum concentrations of p,p'-DDT, p,p'-DDD, HCB and mirex increased, the infant birth weight was also decreased, although the associations were not statistically significant due to the relatively small sample size. These results suggest that p,p'-DDE, β-BHC, and HCB were the predominant OCPs in the serum of Chinese pregnant women and cord blood of their newborns. Prenatal exposure to DDT, β-BHC, HCB, and mirex were asso- ciated with a decrease in birth weight, but these results need validation in larger sample-sized studies. © 2014.


Li Z.-X.,Sun Yat Sen University | Li Z.-X.,Cancer Hospital of Henan province | Yang H.,Sun Yat Sen University | She K.-L.,Sun Yat Sen University | And 6 more authors.
Journal of Cardiothoracic Surgery | Year: 2013

Background: Segmental nodes are not examined routinely in current clinical practice for lung cancer, the role of segmental nodes in pathological staging of non-small cell lung cancer after radical resection was investigated.Methods: A total of 113 consecutive non-small cell lung cancer patients who underwent radical resection between June 2009 and December 2011 were retrospectively reviewed. All the operations were performed by the same group of surgeons. N2 nodes, hilar nodes, interlobar nodes and some lobar nodes were collected during surgery. The removed lung lobes were dissected routinely along lobar and segmental bronchi to collect lobar nodes and segmental nodes. The collected lymph nodes were separately labeled for histological examination.Results: The detection rates of hilar nodes, interlobar nodes, lobar nodes and segmental nodes were 61.1%, 85.0%, 75.2% and 80.5%, respectively. The metastasis rates of hilar nodes, interlobar nodes, lobar nodes and segmental nodes were 5.3%, 10.5%, 16.8% and 14.2%, respectively. There were 68 cases of N0 disease, 16 cases of N1 disease and 29 cases of N2 disease. If an analysis of segmental lymph nodes had been omitted, six patients (37.5% of N1 disease) would have been down-staged to N0, and two cases of multiple-zone N1 disease would have been misdiagnosed as single-zone N1 disease, one patient would have been misdiagnosed as N2 disease with skip metastases.Conclusion: Segmental nodes play an important role in the accurate staging of non-small cell lung cancer, and routinely dissecting the segmental bronchi to collect the lymph nodes is feasible and may be necessary. © 2013 Li et al.; licensee BioMed Central Ltd.


Liu L.,First Peoples Hospital of Zhengzhou | Chen X.,Cancer Hospital of Henan Province | Gao M.,Zhengzhou University
Chinese Journal of Clinical Oncology | Year: 2011

Objective: To investigate the response rate and adverse reactions in patients with advanced or metastatic gastric cancer treated with the regimen of Docetaxel in combination with Oxaliplatin and Capecitabine. Methods: Fifty-six patients were treated with the regimen as follows: Docetaxel 75mg/m2, intravenous, day 1; Oxaliplatin 85mg/m2, intravenous, day 2; Capecitabine 1000mg/m2, twice a day, PO, for 14 days, 21 days for each cycle. Evaluation was performed at the end of 2 cyeles. Results: All of these 56 patients were evaluable for response. Six (10.7%) patients achieved complete response (CR), 30 (53.6%) patients had partial response (PR), 12 (21.4%) patients had stable disease (SD), 8 (14.3%) patients had disease progression (DP), with a total response rate ( RR) of 64.3%. The median progression-free survival was 6.2 months (3.6-11.8 months) and the median overall survival time was 11.6 months (5.9-14.6 months). The most common adverse effects were myelosuppression, gastrointestinal toxicities and neurotoxicity. No chemotherapy-related death was observed. Conclusion: Docetaxel combined with Oxaliplatin and Capecitabine is effective for advanced gastric cancer, with tolerable side effects.

Loading Cancer Hospital of Henan Province collaborators
Loading Cancer Hospital of Henan Province collaborators